STOCK TITAN

Entrada Therapeutics, Inc. - TRDA STOCK NEWS

Welcome to our dedicated page for Entrada Therapeutics news (Ticker: TRDA), a resource for investors and traders seeking the latest updates and insights on Entrada Therapeutics stock.

Entrada Therapeutics, Inc. (TRDA) is a clinical-stage biopharmaceutical company pioneering intracellular therapeutics through its proprietary EEV™ platform. This page provides investors and industry observers with timely updates on clinical developments, strategic partnerships, and regulatory milestones.

Access consolidated news about TRDA's innovative approach to neuromuscular diseases and other complex conditions. Track progress across their pipeline, including Phase 1/2 trials for Duchenne muscular dystrophy candidates and platform expansions into new therapeutic areas.

Key updates include:
• Clinical trial results
• Research collaborations
• Regulatory filings
• Strategic initiatives

Bookmark this page for direct access to verified TRDA announcements and analysis. Check regularly for developments in intracellular medicine advancements and their potential impact on patient care.

Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA) announced that it is on track to submit an Investigational New Drug (IND) application for ENTR-601-44, targeting Duchenne muscular dystrophy (DMD), in Q4 2022. The company holds $244 million in cash and equivalents, ensuring a cash runway into 2H 2024. R&D expenses surged to $16.2 million from $6.8 million year-over-year, with a net loss of $23.2 million for Q2 2022. Entrada also presented promising preclinical data for its therapeutic candidates and initiated collaborations aimed at accelerating developments in neuromuscular disease treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
-
Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA) has announced a collaboration with the Myotonic Dystrophy Clinical Research Network (DMCRN) to support the END-DM1 study, which aims to understand disease progression in myotonic dystrophy type 1 (DM1). This non-interventional study will provide critical data for future clinical trials. Entrada's clinical candidate, ENTR-701, is being developed to potentially treat DM1, with new preclinical data indicating improved therapeutic effects in mouse models. The company plans to file an IND application for ENTR-701 in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
-
Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA) announced the appointment of Karla MacDonald as Chief Corporate Affairs Officer, effective immediately. Ms. MacDonald, previously the Vice President of Corporate Communications and Investor Relations, will report to Dipal Doshi, President and CEO. Her extensive experience in biopharmaceutical communications and stakeholder engagement supports Entrada's focus on developing Endosomal Escape Vehicle (EEV™) therapeutics, particularly for neuromuscular diseases like Duchenne muscular dystrophy. The company is transitioning into a clinical stage entity this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.81%
Tags
management
Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA) announced its participation at the William Blair Biotech Focus Conference in New York on July 12-13, 2022. A fireside chat featuring Dipal Doshi and Natarajan Sethuraman will be available for viewing starting July 11, 2022, at 9:00 a.m. ET on the company’s website, with a 90-day replay. Entrada focuses on developing Endosomal Escape Vehicle (EEV™) therapeutics to target previously inaccessible intracellular sites, targeting diseases like Duchenne muscular dystrophy and myotonic dystrophy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
conferences
-
Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA), a biopharmaceutical company focused on advancing Endosomal Escape Vehicle (EEV™) therapeutics, announced its participation in the Goldman Sachs Global Healthcare Conference. The event will feature a fireside chat with President and CEO Dipal Doshi on June 14, 2022, at 2:40 p.m. PT in Rancho Palos Verdes, CA. A live webcast will be available on the company’s website, with a replay accessible for 90 days afterward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.24%
Tags
conferences
-
Rhea-AI Summary

Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced its second clinical candidate, ENTR-701, aimed at treating myotonic dystrophy type 1. The company is on track to submit an Investigational New Drug application for ENTR-601-44, targeting Duchenne muscular dystrophy, in Q4 2022. As of March 31, 2022, Entrada has $263.9 million in cash and equivalents, projecting sufficient funds to support operations into the second half of 2024. However, the first quarter of 2022 reported a net loss of $21.7 million, significantly higher than the $8.4 million loss in Q1 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.25%
Tags
Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA) has shared promising non-human primate data for its lead candidate, ENTR-601-44, indicating a durability of response for 12 weeks in treating Duchenne muscular dystrophy (DMD). The company also introduced ENTR-701, targeted at myotonic dystrophy type 1 (DM1). Both candidates are set for Investigational New Drug applications: ENTR-601-44 in Q4 2022 and ENTR-701 in 2023. These advancements reinforce Entrada's commitment to developing intracellular therapeutics with potential for transformative patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.44%
Tags
none
-
Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA) announced that CEO Dipal Doshi will present virtually at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation will be accessible starting May 23, 2022, at 7:00 a.m. ET on the company's website. A replay will be available for 90 days after the event.

Entrada focuses on Endosomal Escape Vehicle (EEV™) therapeutics to deliver medicines intracellularly, particularly for conditions like Duchenne muscular dystrophy and myotonic dystrophy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.84%
Tags
conferences
-
Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA) reported financial results for the fourth quarter and full year ending December 31, 2021. The company secured approximately $209 million from its IPO and held $291.1 million in cash as of year-end. Planned developments include submitting an IND application for ENTR-601-44 targeting Duchenne muscular dystrophy in the second half of 2022. R&D expenses rose to $12.4 million for Q4 2021, with a net loss of $18.4 million. G&A expenses also increased significantly, reflecting higher personnel and professional fees.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.78%
Tags
Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA) will have its CEO, Dipal Doshi, participate in the Neuromuscular Panel at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 9:10 a.m. ET. The event aims to discuss the company’s innovative therapeutics, specifically its Endosomal Escape Vehicle (EEV™) technology. A live webcast will be available on Entrada’s website, with a replay accessible for 90 days post-event. The company focuses on developing treatments for neuromuscular diseases and has a robust portfolio targeting conditions like Duchenne muscular dystrophy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.21%
Tags
conferences
Entrada Therapeutics, Inc.

Nasdaq:TRDA

TRDA Rankings

TRDA Stock Data

295.49M
30.24M
17.5%
82.12%
3.68%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON